This study confirms the role of m6A-SNPs in influencing endocrine therapy resistance in ER+ breast cancer, highlighting how modifications mediated by specific SNPs, particularly in FILIP1L and TOM1L1, impact key regulatory pathways and cellular metabolism. This evidence concerns the gene TOM1L1 and breast carcinoma.